Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide / Glycopyrronium / Formoterol)
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
250actual
Sites
20
Country
Italy
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-06-01 | actual | When the study began enrolling |
| Primary completion | 2025-05-31 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-31 | actual | The whole study's end, after follow-up |
| First posted | 2023-05-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Obstructive Pulmonary Disease
Intervention
- Drug: BGF (budesonide/glycopyrrolate/formoterol fumarate)
Primary outcome
what the primary-completion date above is the date OFCOPD Assessment Test (CAT) score
measured baseline, 12 weeks after treatment start
Publications
- PMID 30863039 — cited as background
- PMID 33688176 — cited as background
- PMID 30401700 — cited as background
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed